PDEXHealthcare · Medical Instruments & SuppliesThe 1 Wall Street analysts covering Pro-Dex, Inc. hold a median 12-month price target of $74 — +16.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pro-Dex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PDEX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | $70 → $74 |
| 12 May 2026 | Ascendiant Capital | Maintains | Buy | — |
| 12 May 2026 | Ascendiant Capital | Maintains | Buy | $56 → $70 |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Feb 2025 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 9 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 4 Jan 2017 | Ascendiant Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PDEX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Pro-Dex, Inc. returned +88.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 43% of US stocks
Cheaper than 46% of US stocks
Cheaper than 24% of US stocks
Cheaper than 29% of US stocks
Higher than 55% of US stocks
Higher than 15% of US stocks
Higher than 41% of US stocks
Higher than 75% of US stocks
Higher than 77% of US stocks
Higher than 86% of US stocks
Higher than 95% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pro-Dex, Inc. has a market value of $192.2M and an enterprise value of $190.5M.
Revenue in the twelve months to 30 June 2026: $77.5M. The latest quarter grew 11.0% year on year.
Net income over the same four quarters: $13.7M, a 17.6% net margin.
Free cash flow in the twelve months to 30 June 2026: $6.8M.
Pro-Dex, Inc. spent $3.4M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 16.6×; forward P/E: 18.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pro-Dex, Inc. employs 201 people — $386K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pro-Dex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pro-Dex reported quarterly earnings of $0.92 per share, above the Zacks Consensus Estimate of $0.67. Earnings were $0.62 per share in the year-ago quarter.
Why it matters — PDEX watchers may note the company’s reported earnings exceeded the consensus estimate and were higher than a year earlier.
Ahead of fiscal Q1 earnings, Pro-Dex has strong medical-device sales and margin momentum, while customer concentration, a shrinking backlog and acquisition risks remain concerns.
Why it matters — PDEX watchers are weighing sales and margin momentum against risks that could affect the company's growth.
Zacks Investment Research highlighted five medical supply stocks—MCK, CAH, BDX, MMSI and PDEX—as worth watching amid improving industry prospects. PDEX was included on this list of companies with strong potential.
Why it matters — PDEX being named among five medical supply stocks to watch signals that it is gaining attention as a potential beneficiary of improving industry conditions.
SRK Fund I, LP posted a 26.80% gain in the first half of the year, outperforming the S&P 500's 10.18% and the Russell 2000's 22.57%. The update highlights ImmuCell's strong first-quarter results and Outdoor Holding Company's shift to a pure-play, asset-light GunBroker.com marketplace after divesting its ammunition business.
Why it matters — A PDEX watcher would care because the update covers portfolio companies and performance trends within the same investing ecosystem that Pro-Dex, Inc. operates in.
Zacks Investment Research reported that Pro-Dex, Inc. (PDEX), along with APH and RELY, was added to its Zacks Rank #1 (Strong Buy) momentum stocks list on September 18th, 2026.
Why it matters — A PDEX watcher would care because inclusion on Zacks' Strong Buy momentum list signals a positive research rating for the stock at that time.
The 1 Wall Street analysts covering Pro-Dex, Inc. have a median 12-month price target of $74, with estimates ranging from $74 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Pro-Dex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pro-Dex, Inc. 95 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Pro-Dex, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +16.6% from the last close, and Ticker Nerd's factor model ranks Pro-Dex, Inc. 95 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pro-Dex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDEX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $74 over the next 12 months.
Pro-Dex, Inc. returned +88.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass Estimates". Pro-Dex reported quarterly earnings of $0.92 per share, above the Zacks Consensus Estimate of $0.67. Earnings were $0.62 per share in the year-ago quarter.
Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers. Pro-Dex Inc. focuses on autoclavable, battery-powered, and electric surgical drivers and shavers used in orthopedic, thoracic, and craniomaxillofacial procedures. The company also provides engineering, quality, and regulatory consulting services, supporting customers from product design through production. In addition, it produces rotary air motors and related precision components for a range of industrial applications. Pro-Dex Inc. serves medical device distributors, OEMs, and other industrial customers, making it an important supplier in specialized precision manufacturing and surgical technology markets. Headquartered in Irvine, California, Pro-Dex Inc. combines contract manufacturing capabilities with in-house design expertise to deliver customized medical and industrial solutions.
CEO Mr. Richard Lee Van Kirk Jr. · 201 employees · United States · https://www.pro-dex.com
